Infezioni invasive da Enterobacteriaceae Carbapenemico-Resistenti (CRE): da colonizzato a sepsi, quali fattori di rischio ? Roberto Luzzati Malattie Infettive,

Slides:

Advertisements

Similar presentations

TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.

Advertisements

Edward L. Goodman, MD Core Faculty Hospital Epidemiologist June 27, 2013.

Resistant Gram-negative Infections 21 st March 2013 Acute Medicine Study Day Dr Sarah Glover Consultant in Medical Microbiology and Infectious Diseases.

The Rise of Carbapenem Resistant Organisms

Antibiotic treatment choices for SBP Treviso 8 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of Padova.

1 of 2 Universal vs targeted decolonisation to prevent ICU infections: data from REDUCE MRSA trial Huang SS et al. N Engl J Med 2013;368: Multi-centre,

Emerging Antimicrobial Resistance in Texas The new ESBLs.

 Cefixime is quickly establishing in Western countries as a potent broad-spectrum antibiotic with a variety of indications. A multinational, nonrandomized.

Antimicrobial Resistance in N. gonorrhoeae: In Brief 2014 INTRODUCTION Increased action is needed to help prevent and control gonorrhea. Worldwide antimicrobial.

Le malattie immunitarie aumentano il rischio di complicanze infettive? Gianfranca Cabiddu Divisione Nefrologia Azienda Ospedaliera Brotzu- Cagliari.

Clinical Case Study 2: How to deal with an ESBL

BAD BUGS! Alfred DeMaria, Jr., M.D. Massachusetts Department of Public Health.

CEPHALOSPORINS First used clinically in the early 1960’s. First used clinically in the early 1960’s. They have an important role in the modern treatment.

Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.

Antibiotic Monotherapy for Intraabdominal Infections IS BROAD SPECTRUM MONOTHERAPY ANTIBIOTIC TREATMENT ADEQUATE FOR INTRAABDOMINAL INFECTIONS ? Nicolas.

BL+BLIs: Emerging evidences

Warren S. Joseph, DPM, FIDSA Roxborough Memorial Hospital, Phila., PA

Beta lactam antibiotics & Other cell wall synthesis inhibitors

Antibiotic Pearls in the Emergency Department

How to treat MDR pathogens Tobias Welte Department of Respiratory Medicine and Intensive Care Medizinische Hochschule Hannover, Germany.

Do Physicians Find Our AST Reports As Confusing As We Do? Louis B. Rice, M.D. Louis Stokes Cleveland VA Medical Center and Case Western Reserve University.

Antibiotic Update Jon Hiles, PharmD, BCPS

New antibiotics against Gram-positive pathogens for acute bacterial skin and skin-structure infections (ABSSSIs) 3 international, multi-centre, double-blind,

Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.

Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.

Microbiology Nuts & Bolts Antibiotics Part 1 Dr David Garner Consultant Microbiologist Frimley Park Hospital NHS Foundation.

Empirical Therapy for Ventilation Associated Pneumonia Azar. Hadadi Associate Professor of Infectious Diseases.

SPECTRUM OF PANCREATITIS

Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.

Antibiotics Affecting the Bacterial Cell Wall

Pk/Pd modelling : Clinical Implications

Carbapenemases in practice - lessons learnt from spread in our patch, prophylaxis and first/second line treatments Dr Andrew Dodgson Consultant Microbiologist.

CARBAPENEM- RESISTANT ENTEROBACTERIACEAE Kristen Richardson.

MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.

Nuovi orizzonti nella gestione del paziente con infezione grave da Gram-negativi Matteo Bassetti, MD, PhD Infectious Diseases Division Santa Maria Misericordia.

Kennedy University Hospitals

Guideline for the Diagnosis and Management of Adults in LTC with Urinary Tract Infection (Part 2) This is intended as a guide for evidence-based decision-making.

Le candidemie in una coorte di 686 pazienti anziani del Triveneto: analisi dei fattori di rischio per candidemia e mortalità C. Rosin, A. Azzini, M. Merelli,

Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.

Antimicrobial Stewardship 2.0 Hospitalist Best Practice Eileen Barrett, MD, MPH, FACP Division of Hospital Medicine UNMH.

Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,

Multi-Resistant Gram Negative Microorganisms St Elisabeth Hospital Curacao.

HAP and VAP Guidelines Update

Nitroxoline does not result in microbiological eradication in geriatric patients with lower urinary tract infection: a prospective cohort study C. Forstner1,2*,,

Gram Negative Resistance Mechanisms: Running Out of Options

The Role of the Microbiology Laboratory in AMS programs

Cell wall inhibitor Cephalosporins Dr. Naza M. Ali Lec D

Background Goals Methods Conclusions Results

International Journal of Infectious Diseases

Volume 115, Issue 3, Pages 19S-23S (March 1999)

Wasl Mohammed Al-Adsani, DO, PhD, FACP

Matteo Bassetti, MD, PhD Infectious Diseases Division

I nuovi antibiotici per la chemioterapia di precisione nella terapia delle infezioni da gram-negativi MDR Francesco Menichetti, MD Professor of Infectious.

Dr David Garner Consultant Microbiologist

Treatment of Complicated Intra-abdominal Infections

Doripenem vs Meropenem: a summary of International and Belgian published data Françoise Van Bambeke, Unité de Pharmacologie cellulaire et moléculaire Louvain.

Easy synergism for colistin-resistant KPC-producing Klebsiella pneumoniae: the E-test with supplemented agar E. Tagliaferri, C. Tascini, A. Leonildi,

Inside COMBACTE network: global information for a global problem.

What is Lurking Beneath the Surface? The War Against Superbugs

Meropenem-vaborbactam: A New Hope

Making sense of antimicrobial use and resistance surveillance data: application of ARIMA and transfer function models D.L. Monnet, J.-M. López-Lozano,

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

W. -L. Yu, M. -F. Lee, H. -J. Tang, M. -C. Chang, J

G.M. Rossolini, E. Mantengoli Clinical Microbiology and Infection

Infection services in the intensive care unit

Carbapenem-Resistant Enterobacteriaceae in the community

Fighting MDR G-Negative Infections

Outcomes of infections caused by carbapenemase-producing Klebsiella pneumoniae, according to treatment regimen. Outcomes of infections caused by carbapenemase-producing.

Ceftazidime-avibactam (+/- aztreonam) use in Paediatrics

Ceftazidime-avibactam (+/- aztreonam) use in Paediatrics

Presentation transcript:

Infezioni invasive da Enterobacteriaceae Carbapenemico-Resistenti (CRE): da colonizzato a sepsi, quali fattori di rischio ? Roberto Luzzati Malattie Infettive, Ospedale Universitario, Trieste III° Congresso Triveneto di Malattie Infettive Venezia Mestre, 31 Ottobre 2015 Presidente: Prof. Enzo Raise

Emerg Infect Dis 2014 CRE- attributable death rates 26% to 44%

Identification of risk factors for infection with CRE … may help in the empirical therapeuthic decision-making process … may assist in the early implementation of appropiate infection control measures

cortesemente da GM Rossolini

AAC, 2014

AAC, Oct 2015

Clinical / Microbiology (12 d) Abdominal abscess: KPC –S tigecy and colistin –R aminogly (36 d) VAT/VAP: KPC-S colistin –R tigecy and amino (65 d) BSI: KPC – S colistin -R tigecy, aminogly and fosfomycin …… Therapy/Outcome Tigecy + colistin: CURE (renal insuff iciency) Meropenem + colistin: CURE …..

Clinical / Microbiology (12 d) Abdominal abscess: KPC –S tigecy and colistin –R aminogly (36 d) VAT/VAP: KPC-S colistin –R tigecy and amino ( 65 d) BSI: KPC – S colistin -R tigecy, aminog and fosfomycin (72 d) BSI: KPC –R colistin (MIC, 12 ug/ml) Therapy/Outcome Tigecy + colistin: CURE, renal failure Merop + colistin: CURE Merop + colistin + tigecy: FAILURE (persistent BSI-KPC)

Klebsiella pneumoniae - KPC

Ceppi Colistina Resistenti (%)

AAC, 2013

Clinical / Microbiology Abdominal abscess: KPC –S tigecy and colistin –R aminoglycoside VAT/VAP: KPC-S colistin –R tigecy and amino BSI: KPC – S colistin -R tigecy, aminog and fosfomycin (72 d) BSI: KPC –R colistin (MIC, 12 ug/ml) Therapy/Outcome Tigecy + colistin: CURE + renal failure Merop + colistin: CURE Merop + colistin + tigecy: FAILURE (persistent BSI-KPC) Colistin + merop + ertapenem: initial response > FAILURE

Kimberly A. et al.-2015

CEFTAZIDIME-AVIBACTAM: a novel cephalosporin/betalactase inhibitor combination Ceftazidime is a third generation cephalosporin; resistance, especially with gram negative bacilli, is increasing globally Avibactam (NXL 104) is a non betalactam betalactamase inhibitor active in vitro against class A and C and some class D betalactamases Avibactam is being developed in combination with cefatzidime and with ceftaroline Ceftazidime-avibactam is currently in phase III clinical trials for treatment of UTI and IAI complicated

Clinical / Microbiology Abdominal abscess: KPC –S tigecy and colistin –R aminoglycoside VAT/VAP: KPC-S colistin –R tigecy and amino BSI: KPC – S colistin -R tigecy, aminog and fosfomycin BSI: KPC –R colistin (MIC, 12 ug/ml) Therapy/Outcome Tigecy + colistin: CURE + renal failure Merop + colistin: CURE Merop + colistin + tigecy: FAILURE (persistent BSI-KPC) Colistin + merop + ertapenem: initial response > FAILURE Ceftazidime/avibactam 1000 mg /250 mg + ertapenem 1 g: CURE

Sezione TRIVENETO